Entrada Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Entrada Therapeutics, Inc. (TRDA) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income65.63-6.69-94.62-51.16-26.52
Depreciation & Amortization3.772.842.051.100.33
Stock Based Compensation17.9213.119.902.530.33
Change in Working Capital-118.85136.32-11.31-3.420.28
Change in Accounts Receivable2.20-5.880.000.000.00
Change in Accounts Payable0.991.225.29-0.720.63
Change in Other Working Capital-122.041.00-16.40-2.71-0.35
Other Operating Activities-10.027.4610.102.530.00
Net Cash from Operating Activities-41.56139.80-93.79-50.86-25.57
Investing Activities
Capital Expenditures-3.16-5.612.894.58-2.32
Purchases of Investments-437.72-407.21-145.760.000.00
Sales/Maturities of Investments413.08274.43-145.760.000.00
Net Cash from Investing Activities-27.80-138.40-148.65-4.58-2.32
Financing Activities
Common Stock Issued99.6119.410.20190.690.25
Other Financing Activities3.360.000.000.000.00
Net Cash from Financing Activities102.9621.040.48307.4650.09
Summary
Net Change in Cash33.6122.45-241.96252.0222.20
Cash at Beginning of Period71.5549.11291.0639.050.00
Cash at End of Period105.1671.5549.11291.060.00
Free Cash Flow-44.72134.19-96.67-55.44-27.89
Supplemental Disclosures
Income Taxes Paid4.6214.720.000.000.00